VCIM
LRMR icon

Velan Capital Investment Management’s Larimar Therapeutics LRMR Stock Holding History

Velan Capital Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Hold
33,000
– – 0.09% 42
2025
Q4 		$126K Hold
33,000
– – 0.07% 40
2025
Q3 		$107K Hold
33,000
– – 0.1% 43
2025
Q2 		$95.4K Buy
33,000
+5,000
+18% +$11.6K 0.09% 34
2025
Q1 		$60.2K Buy
28,000
+10,000
+56% +$31.6K 0.06% 34
2024
Q4 		$69.7K Buy
+18,000
New +$119K 0.06% 31

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Velan Capital Investment Management's LRMR Position: Q1 2026 in Review

Velan Capital Investment Management held its Larimar Therapeutics (LRMR) position steady in Q1 2026 at 33,000 shares worth $149K. The position accounts for 0.09% of the portfolio, ranked #42.

Velan Capital Investment Management first reported a position in LRMR in Q4 2024 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Velan Capital Investment Management held 33,000 shares of Larimar Therapeutics worth $149K as of Q1 2026.
  • Velan Capital Investment Management left its Larimar Therapeutics share count unchanged in Q1 2026.
  • Larimar Therapeutics made up 0.09% of Velan Capital Investment Management's portfolio in Q1 2026, its #42 holding.
  • Velan Capital Investment Management first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.